AR070264A1 - Derivados de oxazepinopirimidona heteroarilamida sustituidos - Google Patents
Derivados de oxazepinopirimidona heteroarilamida sustituidosInfo
- Publication number
- AR070264A1 AR070264A1 ARP090100241A ARP090100241A AR070264A1 AR 070264 A1 AR070264 A1 AR 070264A1 AR P090100241 A ARP090100241 A AR P090100241A AR P090100241 A ARP090100241 A AR P090100241A AR 070264 A1 AR070264 A1 AR 070264A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- atom
- alkoxy
- alkyl group
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- -1 nitro, cyano, amino Chemical group 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 150000008318 pyrimidones Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 abstract 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 abstract 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Medicamento, proceso, intermediarios. utiles para tratar actividad anormal de GSK3beta. Reivindicacion 1: Un derivado de pirimidona representado por la formula (1) o una de sus sales o uno de sus solvatos o uno de sus hidratos: en la que: Y representa dos átomos de hidrogeno, un átomo de azufre, un átomo de oxigeno o un grupo alquilo C1-2 y un átomo de hidrogeno; Z representa un enlace, un átomo de oxígeno, un átomo de nitrogeno sustituido con un átomo de hidrogeno o un grupo alquilo C1-3, un átomo de azufre, un grupo metileno opcionalmente sustituido con uno o dos grupos elegidos entre un grupo alquilo C1-6, un grupo hidroxilo, alcoxi C1-6, alquilo C1-2 perhalogenado o un grupo amino; R1 representa un anillo de 2, 3 o 4-piridina o un anillo de 2, 4 o 5-pirimidina, estando el anillo opcionalmente sustituido con un grupo alquilo C1-6, alcoxi C1-6 o un átomo de halogeno; R2 representa un átomo de hidrogeno, un grupo alquilo C1-6 o un átomo de halogeno; R3 representa un grupo heterocíclico de 4-15 miembros, estando este grupo opcionalmente sustituido con 1 a 4 sustituyentes seleccionados entre un grupo alquilo C1-6, un átomo de halogeno, alquilo C1-2 perhalogenado, alquilo C1-6 halogenado, hidroxilo, alcoxi C1-6, alcoxi C1-6 halogenado, nitro, ciano, amino, un grupo monoalquilamino C1-6, dialquilamino C2-12, S-alquilo C1-6, C(O)O-alquilo C1-6 o un grupo C(O)O-arilo, un grupo heterocíclico de 4-15 miembros, arilo, O-arilo o un grupo S-arilo, estando los grupos mencionados anteriormente opcionalmente sustituidos con 1 a 4 sustituyentes seleccionados entre un grupo alquilo C1-6, un átomo de halogeno, alcoxi C1-6, C(O)O-alquilo C1-6 o un grupo C(O)O-arilo; R4 representa un átomo de hidrogeno o un grupo alquilo C1-6; y n representa 0 a 3. Reivindicacion 4: Un derivado de pirimidona representado por las formulas (3), (4) y (7) en las que R1 y R2 son como se definieron para el compuesto de formula (1) de acuerdo con la reivindicacion 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290077A EP2085400A1 (en) | 2008-01-29 | 2008-01-29 | Substituted heteroarylamide oxazepinopyrimidone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070264A1 true AR070264A1 (es) | 2010-03-25 |
Family
ID=39495097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100241A AR070264A1 (es) | 2008-01-29 | 2009-01-27 | Derivados de oxazepinopirimidona heteroarilamida sustituidos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8501728B2 (es) |
| EP (2) | EP2085400A1 (es) |
| JP (1) | JP5581220B2 (es) |
| KR (1) | KR20100116591A (es) |
| CN (1) | CN101981039A (es) |
| AR (1) | AR070264A1 (es) |
| AU (1) | AU2009208726A1 (es) |
| BR (1) | BRPI0906714A2 (es) |
| CA (1) | CA2713248A1 (es) |
| EA (1) | EA201070889A1 (es) |
| IL (1) | IL207191A0 (es) |
| MX (1) | MX2010008360A (es) |
| NZ (1) | NZ587066A (es) |
| TW (1) | TW200936141A (es) |
| WO (1) | WO2009095787A1 (es) |
| ZA (1) | ZA201005381B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2085399A1 (en) * | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | substituted arylamide oxazepinopyrimidone derivatives |
| EP2090578A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
| EP2090579A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted heteroarylamide diazepinopyrimidone derivatives |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104220955B (zh) * | 2012-04-02 | 2017-07-28 | 富士通株式会社 | 模块型数据中心 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG13192A (en) | 1976-02-10 | 1982-12-31 | Rhone Poulenc Ind | Nouveaux derives du dithiole-1,2 leur preparation et les compositions qui les contiennent |
| US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
| EP0861238A4 (en) | 1995-11-01 | 2000-03-01 | Merck & Co Inc | HEXAHYDRO-5-IMINO-1,4-HETEROAZEPINE DERIVATIVES AS INHIBITORS OF NITROGEN OXIDE SYTHASE |
| US20030096813A1 (en) * | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
| DE60206946T2 (de) * | 2001-09-21 | 2006-07-27 | Sanofi-Aventis | Substituierte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)onderivate gegen neurodegenerative erkrankungen |
| EP1557417B1 (en) | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
| EP1790649A1 (en) | 2005-11-21 | 2007-05-30 | Sanofi-Aventis | Substituted bicyclic pyrimidone derivatives |
| EP2085399A1 (en) * | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | substituted arylamide oxazepinopyrimidone derivatives |
| EP2090578A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
| EP2090579A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted heteroarylamide diazepinopyrimidone derivatives |
-
2008
- 2008-01-29 EP EP08290077A patent/EP2085400A1/en not_active Withdrawn
-
2009
- 2009-01-21 TW TW098102265A patent/TW200936141A/zh unknown
- 2009-01-27 NZ NZ587066A patent/NZ587066A/en not_active IP Right Cessation
- 2009-01-27 AR ARP090100241A patent/AR070264A1/es unknown
- 2009-01-27 KR KR1020107016901A patent/KR20100116591A/ko not_active Withdrawn
- 2009-01-27 EP EP09706447A patent/EP2247598B1/en active Active
- 2009-01-27 AU AU2009208726A patent/AU2009208726A1/en not_active Abandoned
- 2009-01-27 CN CN2009801109812A patent/CN101981039A/zh active Pending
- 2009-01-27 MX MX2010008360A patent/MX2010008360A/es not_active Application Discontinuation
- 2009-01-27 JP JP2010544811A patent/JP5581220B2/ja not_active Expired - Fee Related
- 2009-01-27 WO PCT/IB2009/000293 patent/WO2009095787A1/en not_active Ceased
- 2009-01-27 EA EA201070889A patent/EA201070889A1/ru unknown
- 2009-01-27 CA CA2713248A patent/CA2713248A1/en not_active Abandoned
- 2009-01-27 BR BRPI0906714-0A patent/BRPI0906714A2/pt not_active IP Right Cessation
-
2010
- 2010-07-25 IL IL207191A patent/IL207191A0/en unknown
- 2010-07-27 US US12/844,270 patent/US8501728B2/en not_active Expired - Fee Related
- 2010-07-28 ZA ZA2010/05381A patent/ZA201005381B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2247598B1 (en) | 2012-10-24 |
| TW200936141A (en) | 2009-09-01 |
| MX2010008360A (es) | 2010-08-30 |
| JP2011510968A (ja) | 2011-04-07 |
| EA201070889A1 (ru) | 2011-04-29 |
| US8501728B2 (en) | 2013-08-06 |
| WO2009095787A1 (en) | 2009-08-06 |
| CA2713248A1 (en) | 2009-08-06 |
| KR20100116591A (ko) | 2010-11-01 |
| US20110015176A1 (en) | 2011-01-20 |
| EP2085400A1 (en) | 2009-08-05 |
| EP2247598A1 (en) | 2010-11-10 |
| ZA201005381B (en) | 2011-10-26 |
| NZ587066A (en) | 2011-12-22 |
| BRPI0906714A2 (pt) | 2015-06-30 |
| IL207191A0 (en) | 2010-12-30 |
| AU2009208726A1 (en) | 2009-08-06 |
| JP5581220B2 (ja) | 2014-08-27 |
| CN101981039A (zh) | 2011-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066606A1 (es) | Compuestos de heteroarilamida pirimidona | |
| AR070263A1 (es) | Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR070274A1 (es) | Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR070273A1 (es) | Derivados de heteroarilamida diazepinopirimidinona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| CO6220878A2 (es) | Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo | |
| CO6270309A2 (es) | Inhibidores tetrahidropiranocromeno de gamma secretasa | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| DOP2012000318A (es) | Compuestos heterociclicos fusionados | |
| PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
| NI200900037A (es) | Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. | |
| AR060401A1 (es) | Derivados de cromen-2-ona | |
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| CO6331462A2 (es) | Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| ECSP088926A (es) | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR072225A1 (es) | Derivados de alquil pirimidin-4-ona sustituidos y procedimiento para prepararlos | |
| CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |